SCHEMBL20394347

SCHEMBL20394347

COc1ccccc1-c1cccnc1Oc1ccc(OCc2ccccc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
PDE10A Q9Y233 5/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PABPC1 P11940 1/20 0.42
ACACB O00763 2/20 0.41
ACACA Q13085 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ATM Q13315 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
ELANE P08246 1/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LTA4H P09960 1/20 0.39
MAPK14 Q16539 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394225 0.92 HSD17B10 (0.46) KDM4EMAPTPDE10ACYP1A2CYP3A4
SCHEMBL20394239 0.92 MEN1 (0.44) PDE10AMEN1KMT2APABPC1ACACB
SCHEMBL20394497 0.91 PDE10A (0.50) KDM4EMAPTPDE10AMEN1KMT2A
SCHEMBL20394316 0.89 CYP11B1 (0.47) KDM4EMAPTPDE10AELANELTA4H
SCHEMBL20406788 0.87 NPC1 (0.54) KDM4EMAPTPDE10AMEN1KMT2A
SCHEMBL20394271 0.86 MAPT (0.45) KDM4EMAPTPDE10AMEN1KMT2A
SCHEMBL20406447 0.84 ACACB (0.46) MEN1KMT2APABPC1ACACBACACA
SCHEMBL20406193 0.82 PDE10A (0.43) PDE10ARAB9AELANE
SCHEMBL20394304 0.81 GRM5 (0.47) KDM4EMAPTPDE10AELANE
SCHEMBL20394359 0.81 PDE10A (0.45) PDE10AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA KDM4E 2642/4885MAPT 4703/4885PDE10A 4605/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA KDM4E 2642/4885MAPT 4703/4885PDE10A 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.